Q1 2025 · 13F-HR
Octagon Capital Advisors LPholdings as filed
Filed 2025-05-15 · accession 0001839435-25-000004
$516.8M
Reported value
34
Positions
2025-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 87164F105 | SNDX | NUVATION BIO INC | $48.1M | 9.31% | 27,330,800 | Common | SOLE |
| 19240Q201 | COGT | APELLIS PHARMACEUTICALS INC | $45.8M | 8.86% | 2,094,000 | Common | SOLE |
| 578784100 | MAZE | DIANTHUS THERAPEUTICS INC | $42.5M | 8.22% | 2,341,667 | Common | SOLE |
| 252828108 | DNTH | ARRIVENT BIOPHARMA INC | $38.1M | 7.37% | 2,059,387 | Common | SOLE |
| 89157D105 | TRML | TREVI THERAPEUTICS INC | $33.0M | 6.38% | 4,091,815 | Common | SOLE |
| 38341P102 | GOSS | CENTESSA PHARMACEUTICALS PLC | $20.5M | 3.97% | 1,425,000 | Common | SOLE |
| 60255C885 | BRD1EUR | GOSSAMER BIO INC | $20.2M | 3.91% | 18,350,000 | Common | SOLE |
| 877619106 | TSHA | OCULAR THERAPEUTIX INC | $17.8M | 3.44% | 2,425,000 | Common | SOLE |
| 46489V302 | CATX | MIND MEDICINE MINDMED INC | $17.7M | 3.42% | 3,018,000 | Common | SOLE |
| 482929106 | KLRS | COGENT BIOSCIENCES INC | $16.6M | 3.20% | 2,763,000 | Common | SOLE |
| 64135M105 | NGNE | KALVISTA PHARMACEUTICALS INC | $15.8M | 3.06% | 1,370,000 | Common | SOLE |
| 03770N101 | APGE | TAYSHA GENE THERAPIES INC | $14.9M | 2.88% | 10,700,000 | Common | SOLE |
| 80706P103 | SRRK | NUVATION BIO INC | $13.9M | 2.69% | 7,900,000 | Common | SOLE |
| 44486Q103 | HUMA | VERONA PHARMA PLC | $13.8M | 2.67% | 217,264 | Common | SOLE |
| 92790C104 | VRDN | TOURMALINE BIO INC | $13.8M | 2.66% | 905,000 | Common | SOLE |
| N69605108 | PHVS | MERUS N V | $13.0M | 2.51% | 308,000 | Common | SOLE |
| 67576A100 | OCUL | MOONLAKE IMMUNOTHERAPEUTICS | $11.6M | 2.24% | 296,000 | Common | SOLE |
| 90466Y103 | — | SYNDAX PHARMACEUTICALS INC | $11.1M | 2.15% | 904,000 | Common | SOLE |
| 21833P301 | CRBP | ATYR PHARMA INC | $10.7M | 2.08% | 3,552,000 | Common | SOLE |
| 925050106 | VRNA | SCHOLAR ROCK HOLDING CORP | $10.6M | 2.05% | 329,000 | Common | SOLE |
| 45256X103 | IBRX | VERASTEM INC | $10.4M | 2.01% | 1,720,000 | Common | SOLE |
| G4444H101 | BBOT | CENTESSA PHARMACEUTICALS PLC | $8.6M | 1.67% | 600,000 | PUT | SOLE |
| 89532M101 | TRVI | REGULUS THERAPEUTICS INC | $8.1M | 1.57% | 4,637,076 | Common | SOLE |
| 92337C203 | VSTM | ARS PHARMACEUTICALS INC | $7.9M | 1.52% | 625,000 | Common | SOLE |
| 152309100 | CNTA | ABIVAX SA | $7.7M | 1.49% | 1,230,000 | Common | SOLE |
| N5749R100 | 2GH | ERASCA INC | $7.0M | 1.36% | 5,136,795 | Common | SOLE |
| 14070B309 | CAPR | VIRIDIAN THERAPEUTICS INC | $6.1M | 1.17% | 450,000 | Common | SOLE |
| 483497103 | KALV | CORBUS PHARMACEUTICALS HLDGS | $5.9M | 1.15% | 1,115,000 | Common | SOLE |
| 002120202 | ATYR | UNICYCIVE THERAPEUTICS INC | $5.7M | 1.11% | 10,000,000 | Common | SOLE |
| 67080N119 | NUVB/WS | MAZE THERAPEUTICS INC | $5.2M | 1.00% | 468,000 | Common | SOLE |
| 29479A108 | ERAS | PERSPECTIVE THERAPEUTICS INC | $4.8M | 0.93% | 2,250,000 | Common | SOLE |
| 67080N101 | NUVB | KALARIS THERAPEUTICS INC | $3.9M | 0.75% | 481,000 | Common | SOLE |
| 75915K309 | RGLS | NEUROGENE INC | $3.5M | 0.69% | 303,000 | Common | SOLE |
| 61559X104 | MLTX | HELIX ACQUISITION CORP II | $2.8M | 0.55% | 250,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.